		•	iality Improvem						_											
	Туре	Raised by	Date Raised Owner	Workstream / Project Area	Risk Description	Impact Description	Primary Category	Impact:1 (1-5)	Likelihood:1 (1-5)	R A G	Secondary Category	Impact:2 (1-5)	likelihood 2 (1-5)	R A G	Mitigation Strategy	Strategic Objective	health Impact	Potential Adverse Health Impac		Drop down
										1				2						
				Project Programme	There is a risk of slippage to project objectives that may cause failure to deliver on objectives within the project timescale	project objectives will not be achieved with resulting business / reputation risk	Business				Reputation					Customer at he of everything v	I	Nil ( no clinical impact)		
NSQIG 01	Risk	A Macleod	16/07/2018 Craig Stewart	t	within the project timescale	reputation risk			4 3	12	2		2 1	L	2 Reduction				Open	Workstream
				Project Programme		Failure to secure resources for analytics and G.P sessinal time will impact on project deliverabels	Business				Reputation				Reduction	Improve the way	ay Zero	Nil ( no clinical impact)		
NSQIG 02	Risk	A Macleod	16/07/2018 Craig Stewart	t					4 3	12	2		2 2	2	4				Open	Project Programme
				Engagement	There is a risk that NSQIG fails to engage with key stakeholder groups	Potential political or clinical challenge that may impact on delivering project objectives	g Business				Reputation				Prevention	Customer at he of everything v do	I	Nil ( no clinical impact)		
NSQIG 03	Risk	A Macleod	16/07/2018 Craig Stewart	t	There is a risk that the project	delays in delivery of			4 3	12	2		2 3	3	6	Customer at he	part Zoro	Nil ( no clinical		Engagement
				Engagement		project with concerns	Staff				Reputation				Prevention	of everything v		impact)		
NSQIG 04	Risk	A Macleod	16/07/2018 Craig Stewart	t	There is a risk that the metrics	Reduced ability to			3 3	g	9		2 3	3	6	Improve the w	av 7ero	Nil ( no clinical		Optimal Stoma Prescribing Data
				Optimal Stoma Prescribin Data	developed do not support	Reduced ability to identify opportunities to deliver clinical benefits	Staff				Business					we do things	ay   ZelU	impact)		
NSQIG 05	Risk	A Macleod	16/07/2018 Craig Stewart	National Formulary	There is a risk that Health Boards may not support a national formulary	Reduced ability to deliver Once for Scotland objective	Clinical		3 2	(	Reputation		2 2	2	4 Prevention	Improve the way	ay Zero	Nil ( no clinical impact)		National Formulary
NSQIG 06	Risk	A Macleod	16/07/2018 Craig Stewart						3 3	,	9		2 2		4 Prevention				Open	Prescribing Models
NSQIG 07		A Macleod	Mhairi 16/07/2018 Hastings	Prescribing Models	There is a risk that process mapping activities fail to identify alternative models of stoma prescribing	Failure to develop prescribing models option appraisels	Clinical		3	-	Reputation		2		4 Prevention	Improve the way	ay Zero	Nil ( no clinical impact)		PROMs Reporting
NSQIG 08	KISK	A Macieou	10/07/2016 Hastings	PROMs Reporting					5		<del>3</del>		2	2	4 Prevention				Open	e-health opportunities
NSQIG 09				e-health opportunities											0					Industry Partnership
NSQIG 10				Industry Partnership											0					Clinical & Financial Benefits
NSQIG 11				Clinical & Financial Benefits											0					Primary Category
113Q10 11															0					Clinical Business
															0					Staff Reputation
															0					Secondary Category Clinical Business
																				Staff Reputation Mitigating Strategy
																				Acceptance Contingency Prevention Reduction
																				Transference Strategic Objective (NSS) Customer at heart of everything
																				Increase Service Impact Improve the way we do things Health Impact
																				Zero <5K 5-50K
																				50K-500K 500K-5M >5M
																				Potential Adverse health impact Nil ( no clinical impact) Realisation of minor adverse
																				event ( clinical impact 2 minor ) Disruption to provision of clinical services ( clinical impact 3 moderate) Moderate reversible effect on
																				health (clinical impact 3 moderate) Irreversible effect on health status (clinical impact 4 major)
																				Severe adverse evetn occurs (clinical impact 5 catastrophic )  Status  Open

## **Mitigating Actions**

			<b>Chair Review</b>	
ID	Risk Description	Mitigating Actions	Outcome	Change comments
	There is a risk of slippage to project objectives that may cause failure to deliver on objectives within the project timescale	1. Project chair / co - chair & Pmg to track progress against agreed project plan timescales 2. Progress of quarterly report to SDNDG & PTP 1st report to be completed for July 31 following steering group meeting on 23.07.18		
	There is a risk that NSQIG is unable to secure resources for analytics and G.P sessional time to suppport the project	Project chair / PMg have e-maile confirmation of funding via Procurement Transformation     Programme (PTP)     Chair & PMg to track activity meeting funiding agreement		
-	There is a risk that NSQIG fails to engage with key stakeholder groups	1. Chair approval to send Communication SBAR & ToR to key stakeholder groups:  SEND/ SDNDG/ Directors of Pharmacy / SSF  2: NSQIG members to link with key professinal / Health Board groups  3: Patient representation doisucssed: To identify most effective strategies to support patient involvement		
NSQIG 04	There is a risk that the project members are uncertain what is expected of them leading to poor engagement and progress of project plan	<ol> <li>Steering group minutes and action plan approved at each meeting.</li> <li>Escalation of any concerns to Chair &amp; Co - Chair</li> </ol>		
	There is a risk that the metrics developed do not support optimal datra reporting	1. Baseline metrics progressed with project analysts :presentation to Steering Group 23.07.18		
	There is a risk that Health Boards may not support a national formulary	1. Chair to discuss outc0omes from process mapping execrcise		
-	There is a risk that process mapping activities fail to identify alternative models of stoma prescribing	<ol> <li>Chair to discuss outcomes of procvess mapping excericse and plan on how we progress prescribing models.</li> <li>G.P representatoives keen to progress alternative to G.P prescribing: first G.P attendance at 23.07.18 meeting</li> </ol>		

Mitigation Strategy Acceptance Tolerate the risk, perhaps because nothing can be done at a reasonable cost to mitigate it or the likelihood and impact of the risk occurring are at an acceptable level. Contingency These are actions planned and organised to come into force after the risk occurs. All actions taken to manage issues are contingency actions. Prevention Prevention actions are usually taken to reduce the likelihood of the risk occurring and before the risk is expected to occur (i.e. before the risk date). Reduction Reduction actions are taken to reduce the impact on the risk to acceptable levels. Reduction actions are also taken in advance of the risk occurring. This is a specialist form of risk reduction where the management of the risk is passed to a third party via, for instance, an insurance policy or penalty clause, such that the impact of the risk is no longer an issue for the health of the programme/work package. Not all risks can be transferred in this way. Transference

The Likelihood and Impact scores are combined by multiplication to give a Risk Rating or RAG score. This indicates how risks should be prioritised.

			Likelihood					
			Rare	Unlikely	Possible	Likely	Almost Certain	
	Î	Score	1	2	3	4	5	
	Catastrophic	5	5	10	15	20	25	
t t	Major	4	4	8	12	16	20	
Impact	Moderate	3	3	6	9	12	15	
=	Minor	2	2	4	6	8	10	
	Negligible	1	1	2	3	4	5	

KEY		
Risk Rating	RAG/ Combined Score	Action/Treatment
HIGH	15 – 25	Poses a serious threat. Requires immediate action to reduce/mitigate the risk.
MEDIUM	9 – 12	Poses a threat and should be pro-actively managed to reduce/mitigate the risk.
LOW	1 - 8	Poses a low threat and should continue to be monitored.

## **Health Impact**

Number of people affected	Extent of potential adverse health impact					
Zero	0 = Nil					
Less than 5,000	1 = Realisation of minor adverse event. Small adverse impact on health status.					
5,000 - 50,000	2 = Disruption to provision of clinical services resulting in minor treatment delays.					
50,000 - 500,000 Likely to apply where the focus of our activity is within secondary care	3 = Moderate reversible adverse effect on health status. Disruption to provision of clinical services resulting in unacceptable delays to treatment.					
500,000 - 5,000,000 Likely to apply where the focus of our activity encompasses both secondary and primary care.	4 = Irreversible effect on health status through extensive injury or major harm. Sustained loss of service.					
More than 5,000,000. Relevant where the focus is on public health or population-wide activity.	5 = Severe adverse event occurs Death or long term morbidity Complete loss or permanent discontinuation of services.					

## **Strategic Objectives** (NSS)

- 1 Customers at heart of everything we do
- 2 Increase our service impact
- 3 Improve the way we do things

( customers relate to HB staff or

Be a great place to work (this is omitted as ?? Not relevant to NSQIG as specific to N

patients)

NSS)